Coexisting myelin oligodendrocyte glycoprotein antibody-associated disease and spinal dural arteriovenous fistula: A diagnostic and neuroimmunological challenge.

J NeuroimmunolJun 1, 2026 (epub)
Case ReportNeurology

Changman Deng, Yiran Zhang, Jie Shen et al.

✦ AI-curated · Sources linked

Case in brief

A 78-year-old woman presented with worsening bilateral lower limb numbness, weakness, and fecal incontinence over two months. MRI revealed a longitudinally extensive spinal cord lesion, and serological tests confirmed MOG antibodies at a titer of 1:100. After glucocorticoid treatment, she showed partial improvement, but further imaging revealed a spinal arteriovenous malformation, highlighting diagnostic complexities.

Diagnostic / clinical pearl

This case illustrates that the presence of MOG antibodies and partial response to glucocorticoids do not exclude the possibility of concurrent vascular pathologies in patients with myelopathy.

Why it matters

The findings emphasize the need for thorough diagnostic evaluations, including vascular imaging, in cases of atypical or progressive myelopathy to avoid misdiagnosis.

Source

Published in J Neuroimmunol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.